• Home
  • Topic
    • COVID-19
    • New Drugs
    • Oncology
    • Cardiology
    • Metabolism
    • Neuroscience
    • Autoimmune Diseases
    • Infections
    • Rare/Orphan Diseases
    • Drug Safety
  • Section
    • Pharma & Biotech
    • Regulatory
    • Clinical Trials
    • Mergers & Acquisitions
    • Research
    • In the Pipeline
  • BioPharma News
    • About Us
    • Our Team
    • Contact Us
    • Editorial Policy
    • Terms of Use
    • Privacy Policy
  • Subscribe
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
Skip to content
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
BioPharma News

BioPharma News

Biopharmaceutical industry analysis. Credible, reliable, equitable.

Subscribe
  • Home
  • Topic
    • COVID-19
    • New Drugs
    • Oncology
    • Cardiology
    • Metabolism
    • Neuroscience
    • Autoimmune Diseases
    • Infections
    • Rare/Orphan Diseases
    • Drug Safety
  • Section
    • Pharma & Biotech
    • Regulatory
    • Clinical Trials
    • Mergers & Acquisitions
    • Research
    • In the Pipeline
  • BioPharma News
    • About Us
    • Our Team
    • Contact Us
    • Editorial Policy
    • Terms of Use
    • Privacy Policy
  • Subscribe

Autoimmune Diseases

Ultomiris (ravulizumab).
Posted inAutoimmune Diseases, Rare/Orphan Diseases, Regulatory

Ultomiris: First Drug for Paroxysmal Nocturnal Hemoglobinuria in Children and Adolescents

by Julia Mardi June 11, 2021September 8, 2022

Alexion Pharmaceuticals’ ravulizumab has expanded the range of indications for treating a rare complement-mediated disease.

Posted inAutoimmune Diseases, Neuroscience, New Drugs, Regulatory

Kesimpta: Highly Effective New Drug for Multiple Sclerosis

by Julia Mardi June 4, 2021September 8, 2022

Ofatumumab by Novartis is as good and convenient as Ocrevus by Roche against multiple sclerosis.

Posted inAutoimmune Diseases, New Drugs, Regulatory

Zeposia: New Drug for Ulcerative Colitis

by Julia Mardi June 2, 2021September 8, 2022

Oral ozanimod will provide clinical remission of ulcerative colitis for a third of patients.

blood
Posted inAutoimmune Diseases, New Drugs, Rare/Orphan Diseases, Regulatory

Empaveli: Powerful New Drug for Paroxysmal Nocturnal Hemoglobinuria

by Tanya von Reuss and Alex Avisoni May 20, 2021September 8, 2022

Pegcetacoplan is more effective in treating paroxysmal nocturnal hemoglobinuria compared to Soliris.

Posted inAutoimmune Diseases, Neuroscience, New Drugs, Regulatory

Ponvory: Another Drug for Multiple Sclerosis

by Mark Gubar May 17, 2021September 8, 2022

Ponesimod is a new drug that changes the course of multiple sclerosis and is a direct competitor to Gilenya (fingolimod), Mayzent (siponimod), and Zeposia (ozanimod).

Posted inAutoimmune Diseases, Neuroscience, New Drugs, Regulatory

Zeposia: New Drug to Treat Relapsing Multiple Sclerosis

by Julia Mardi April 21, 2021September 8, 2022

Bristol-Myers Squibb has come up with ozanimod, a direct competitor to Novartis’ fingolimod and siponimod, for the treatment of multiple sclerosis.

Alexion Pharmaceuticals.
Posted inAutoimmune Diseases, Mergers & Acquisitions, Rare/Orphan Diseases

AstraZeneca + Alexion = Rescue of Both Companies

by Alex Avisoni April 18, 2021September 8, 2022

Alexion Pharmaceuticals, which owns Soliris, one of the most expensive drugs on Earth, has agreed to sell AstraZeneca for $39 billion.

Posts pagination

Newer posts 1 2 3 4 Older posts
BioPharma News Logo
Biopharmaceutical industry analysis.
© 2025 BioPharma News Powered by Newspack Privacy Policy
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
BioPharma News

Awareness and enlightenment are strengths.

BioPharma News is an amazing and trustworthy non-profit data analysis service that provides honest and objective reporting on the Pharma & Biotech industry. We would like to invite you to sign up for our weekly Newsletter to stay informed and uptodate.

Please check your inbox or spam folder for an email from [email protected] to confirm your subscription.

×